Edoxaban low dose + Edoxaban high dose

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Deep Vein Thrombosis

Conditions

Deep Vein Thrombosis, Venous Thromboembolism

Trial Timeline

Nov 5, 2014 → Sep 16, 2021

NCT ID

NCT02303431

About Edoxaban low dose + Edoxaban high dose

Edoxaban low dose + Edoxaban high dose is a phase 1 stage product being developed by Daiichi Sankyo for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02303431. Target conditions include Deep Vein Thrombosis, Venous Thromboembolism.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02303431	Phase 1	Completed	Nov 5, 2014	Sep 16, 2021	Deep Vein Thrombosis

Competing Products

20 competing products in Deep Vein Thrombosis

See all competitors

Product	Company	Stage	Hype Score
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin	Daiichi Sankyo	Phase 2	52
Fragmin (dalteparin sodium )	Pfizer	Pre-clinical	22
Fluconazole	Pfizer	Pre-clinical	22
Dalteparin sodium injection + Warfarin	Pfizer	Approved	84
Low Molecular Weight Heparin (dalteparin)	Pfizer	Approved	84
Apixaban + Unfractionated Heparin (UFH) + Warfarin	Pfizer	Phase 3	76
Apixaban	Pfizer	Approved	84
Apixaban	Bristol Myers Squibb	Phase 2	51
Enoxaparin + Placebo + Apixaban + Placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	76
Apixaban	Bristol Myers Squibb	Pre-clinical	22
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin	Sanofi	Pre-clinical	22
Clexane	Sanofi	Approved	84
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)	Sanofi	Phase 3	76
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)	Sanofi	Phase 3	76
Rivaroxaban (Xarelto, BAY59-7939) + Standard of care	Bayer	Pre-clinical	20
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + Warfarin	Bayer	Phase 3	74
Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelines	Bayer	Pre-clinical	20
Triptorelin Acetate 3.75mg intramuscular injection	Ipsen	Pre-clinical	20

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved